Home Monitoring Helps Preserve Vision for Patients at High Risk for...
The results of the Home Monitoring of the Eye (HOME) study, a subset of the Age-Related Eye Disease Study 2 (AREDS2) clinical centers* was presented at the annual meeting of the American Academy of...
View ArticlePotential Topical Treatment in the Future for Macular Degeneration
Researchers at the University of North Carolina School of Medicine have published new findings in the hunt for a better treatment for macular degeneration. In studies using mice, a class of drugs known...
View ArticleNew Initiative by the American Academy of Ophthalmology Harnesses Technology...
The American Academy of Ophthalmology launches the nation’s first comprehensive eye disease and condition patient database. The IRIS™ Registry (Intelligent Research in Sight) made its debut in a...
View ArticleDiscussions on the Retina and AMD from the American Academy of Opthalmology...
A discussion of the latest developments for retinal diseases presented at the 2013 AAO Annual Meeting with Dr. Carl Regillo, Chief of the Retina Service at Wills Eye Hospital in Philadelphia, Dr. Allen...
View ArticleNew Treatment Approach in Mice Regresses Abnormal Vessels in Wet Macular...
Researchers at the University of North Carolina School of Medicine have published new findings in the hunt for a better treatment for macular degeneration. In studies using mice, a class of drugs known...
View ArticleMicroRNAs Block Abnormal Blood Vessel Growth While Still Maintaining the...
The research team from The Scripps Research Institute (TSRI) in California, Mount Sinai Hospital in Canada and the University of California, San Diego (UCSD), say their findings could lead to new...
View ArticlePotential Topical Treatment in the Future for Macular Degeneration
Researchers from the Tufts University School of Medicine have found a possible topical treatment for age-related macular degeneration (AMD) by applying a molecule called PPADS to the eye in the form of...
View ArticleGreatest vision gains occur during early stages of anti-VEGF treatment for...
Visual acuity improved in early stages of treatment with anti-VEGF injections for neovascular age-related macular degeneration, according to a study presented here at the Association for Research in...
View ArticleAs-needed anti-VEGF regimen shown to be effective for the treatment of wet AMD
A meta-analysis of independent studies comparing ranibizumab and bevacizumab carried out at the University of Lyon showed comparable efficacy and a higher incidence of severe systemic effects with...
View ArticleVitreous separation in wet AMD patients linked to fewer anti-VEGF injections
The presence of vitreous separation may play a role in ranibizumab therapy for neovascular age-related macular degeneration, according to a poster presented at the Association for Research in Vision...
View ArticlePositive phase 2 trial results of anti-VEGF abicipar pegol for treating wet AMD
Analysis of data from a Phase 2 study of abicipar pegol (Anti-VEGF DARPin®) in neovascular, or “wet,” age-related macular degeneration (AMD) showed positive results, leading to the decision to advance...
View ArticleOpthea OPT-302 Combo Outshines Lucentis Alone
At EURETINA 2019 Congress, the Australia based company Ophthea reported data that OPT-302 reduced areas of neovascularization by 38% more and decreased scarring by 39% more, compared to Lucentis alone...
View ArticleAMD Incidence to Rise by 75% and Affect 77 million Europeans by 2050
In latest calculations, researchers pooled data from 22 prevalence studies involving 55,323 people, aged, on average, between 60 and 81, and from four incidence studies across Europe … Source: BMJ
View ArticleBeovu Approved for Wet AMD in European Union
Following the Euopean Medicines Agency (EMA) human medicine’s committee recommendation in December, Beovu (brolucizumab) received formal approval by the European Commission … Source: PharmaTimes
View ArticleNovartis Provides Update on Use and Safety of Beovu in Patients With Wet AMD
After the American Society of Retinal Specialists (ASRS) shared a note with its membership warning of vision-threatening cases of occlusive retinal vasculitis of wet AMD drug Beovu, Novartis issued a...
View ArticleFDA approves faricimab for treatment of wet AMD and DME
Faricimab will be the first and only FDA-approved medicine targeting two distinct pathways, Ang-2 and VEGF-A, involved in retinal diseases and may cause vision loss. To see the Angiogenesis...
View Article
